02200nas a2200313   4500000000100000008004100001260000900042653001000051653000900061653002600070653001100096653002900107653003300136653001200169653002500181100001400206700001400220700001400234700001600248700001600264700002500280700001600305700001700321245011700338300000900455490000700464520140100471022001401872       1992                            d  c199210aAdult10aAged10aGallium Radioisotopes10aHumans10aLeishmaniasis, Cutaneous10aLeishmaniasis, Mucocutaneous10aleprosy10aRadionuclide Imaging1 aBraga F J1 aAbreu C M1 aAbreu P R1 aCamargo E E1 aRivitti M C1 aTedesco-Marchesi L C1 aGambini D J1 aBarritault L00a[2 infectious granulomatous diseases (leprosy and cutaneous and mucous leishmaniasis) by scintigraphic methods].  a53-60 v853 a<p>Leprosy is a multiform chronic infectious granulomatous disease caused by Mycobacterium leprae, that affects over 12 million people in the world. Cutaneous and mucous leishmaniasis (CML) is also a chronic granulomatous infectious disease, caused by Leishmania brasiliensis and transmitted to man by the mosquitoes of the Phlebotominae family. It is a worldwide spread disease. We studied one case of Borderline-wirchowian leprosy and 2 cases of CML with Gallium-67 (GA-67) scintigraphy. Ga-67 is a radiopharmaceutical known for its property of concentrating in inflammatory sites. In the leprosy patient, Ga-67 accumulated in the skin in a moderate, homogeneous and disseminated way (outlined skin); in the area of the face, the uptake was important and homogeneous (image in beard). Several internal organs accumulated Ga-67. As for the 2 CML patients, Ga-67 accumulated focally, in different degrees, in the affected anatomical areas. The leprosy patient was not under treatment and the 2 CML were under treatment (20 and 40 days, respectively). In the 3 cases, all affected areas accumulated Ga-67. Intensity differences of uptake may be explained both by different degrees of inflammatory processes (between leprosy and CML) and by treatment lasting. It is possible that Ga-67 scintigraphy may be useful for the evaluation of these 2 diseases extent and also for the therapy follow-up.</p>  a0037-9085